GOLD-concordant inhaled maintenance therapy at hospital discharge after hospitalisation for severe COPD exacerbation: a multicentre retrospective observational study.
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity, with frequent exacerbations resulting in hospitalizations, increased healthcare burdens, and mortality. The GOLD report emphasizes dual or triple inhaler therapy for high-risk (GOLD group E) patients, yet real-world guideline adherence during hospitalization remains unclear. This study aimed to evaluate concordance with GOLD-recommended maintenance inhaler therapy at hospital discharge in patients with severe exacerbations of COPD and to identify factors associated with treatment rates.
We conducted a retrospective, multicentre, observational study of 3928 COPD inpatients across 85 hospitals within the German Helios group (January 2022-September 2024). The primary outcome was the proportion of patients discharged on GOLD-concordant inhaler therapy, defined as dual long-acting bronchodilation (LABA/LAMA), or triple therapy (LABA/LAMA/ICS) in patients with eosinophils ≥300/μL or high exacerbation risk. Secondary outcomes included diagnostic procedures, pharmacological management, hospital characteristics, in-hospital outcomes and predictors of guideline-concordant prescribing assessed using multivariable logistic regression models.
The mean age of the cohort was 70.1 years (SD 10.1), 45% (n = 1784) were female, 75% (n = 2952) had cardiovascular comorbidities and 45% were treated on pneumology wards. Eosinophil counts were measured in 49% (n = 1895) of patients. During hospitalisation, 14% (n = 560) of patients required intensive care, mean length of stay was 6.6 days, and in-hospital mortality was 1.7% (n = 66). In patients with available documentation, at admission, 61% (1344 of 2205) received dual (21%; 455) or triple (40%; 889) maintenance inhaler therapy. At discharge, 77% (2573 of 3326) of patients were prescribed GOLD-concordant inhaler therapy (dual: 28%; 939 and triple: 52%; 1720). In multivariable analyses, guideline-concordant prescribing at discharge was independently associated with longer length of stay (odds ratio [OR] 1.17/day; 95% CI 1.06-1.29), male sex (OR 1.45; CI 1.23-1.71), treatment on a pneumology ward (OR 1.77; 1.42-2.20), and older age (OR 0.87 per standard deviation increase; CI 0.79-0.95).
In this multicentric large, real-world, hospital-based cohort of patients with severe COPD exacerbations, more than one in five patients were discharged without guideline-concordant maintenance inhaler therapy. Specialist pneumological care and structured inpatient management were strongly associated with improved adherence. Hospital care substantially increased maintenance therapy rate. Systematic implementation of eosinophil risk stratification, enhanced specialist involvement, and standardised discharge pathways could be opportunities and may substantially improve evidence-based COPD care and reduce future exacerbation risk.
This study and the preparation of the manuscript were financially supported by AstraZeneca.
We conducted a retrospective, multicentre, observational study of 3928 COPD inpatients across 85 hospitals within the German Helios group (January 2022-September 2024). The primary outcome was the proportion of patients discharged on GOLD-concordant inhaler therapy, defined as dual long-acting bronchodilation (LABA/LAMA), or triple therapy (LABA/LAMA/ICS) in patients with eosinophils ≥300/μL or high exacerbation risk. Secondary outcomes included diagnostic procedures, pharmacological management, hospital characteristics, in-hospital outcomes and predictors of guideline-concordant prescribing assessed using multivariable logistic regression models.
The mean age of the cohort was 70.1 years (SD 10.1), 45% (n = 1784) were female, 75% (n = 2952) had cardiovascular comorbidities and 45% were treated on pneumology wards. Eosinophil counts were measured in 49% (n = 1895) of patients. During hospitalisation, 14% (n = 560) of patients required intensive care, mean length of stay was 6.6 days, and in-hospital mortality was 1.7% (n = 66). In patients with available documentation, at admission, 61% (1344 of 2205) received dual (21%; 455) or triple (40%; 889) maintenance inhaler therapy. At discharge, 77% (2573 of 3326) of patients were prescribed GOLD-concordant inhaler therapy (dual: 28%; 939 and triple: 52%; 1720). In multivariable analyses, guideline-concordant prescribing at discharge was independently associated with longer length of stay (odds ratio [OR] 1.17/day; 95% CI 1.06-1.29), male sex (OR 1.45; CI 1.23-1.71), treatment on a pneumology ward (OR 1.77; 1.42-2.20), and older age (OR 0.87 per standard deviation increase; CI 0.79-0.95).
In this multicentric large, real-world, hospital-based cohort of patients with severe COPD exacerbations, more than one in five patients were discharged without guideline-concordant maintenance inhaler therapy. Specialist pneumological care and structured inpatient management were strongly associated with improved adherence. Hospital care substantially increased maintenance therapy rate. Systematic implementation of eosinophil risk stratification, enhanced specialist involvement, and standardised discharge pathways could be opportunities and may substantially improve evidence-based COPD care and reduce future exacerbation risk.
This study and the preparation of the manuscript were financially supported by AstraZeneca.
Authors
Peukert Peukert, Kwast Kwast, Hohenstein Hohenstein, Pradler Pradler, König König, Bauer Bauer, Armbrust Armbrust, Büchner Büchner, Probst Probst, Laing Laing, Anderson Anderson, Kahnert Kahnert, Bollmann Bollmann, Kuhlen Kuhlen, Gediga Gediga, Rasche Rasche
View on Pubmed